|
Diaceutics PLC on Tuesday said it returned to profit in 2025 supported by revenue growth and an improving order book. The Belfast, Northern Ireland-based diagnostic testing company posted a pretax profit of £302,000 in 2025, swung from a £1.9 million loss the year prior. Revenue rose 20% to £38.4 million from £32.2 million, or by 24% at constant currency, with annual recurring revenue of £20.0 million, up 19% from £16.8 million. Adjusted earnings before interest, tax, depreciation and amortisation jumped 80% to £7.6 million from £4.2 million at a margin of 20%, compared to 13% a year before. The firm said 2025 saw ‘industry-wide challenges’ and ‘shifting market dynamics’. Chief Executive Ryan Keeling said: ‘Against a backdrop of heightened budget discipline across pharma and biotech, we delivered strong revenue growth, returned the business to profitability, and continued to scale our platform globally. Momentum improved through Q4, resulting in a strong finish to the year, and trading year-to-date has remained positive, with Q1 2026 performing in line with the board’s expectations.’ Diaceutics said revenue rose 15% at constant currency in the first three months of 2026 and said the strength of its order book and pipeline provides confidence that targets for 2026 are on track. At the end of 2025, the order book stood at £38.9 million, up 56% on-year, with order book visibility for the next 12 months £21.1 million, up 19%. Shares in Diaceutics fell 8.9% to 151.70 pence each in London on Tuesday. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
